Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by toinv261on Aug 14, 2015 4:11pm

74 Views

Post# 24020064

RE:RE:RE:INTERESTING ARTICLE RE CVS AND DRUG PRICING FYI

BDAZ, thanks for straightening me out and giving us the facts and science.

I find it remarkable how you can weave through all of the research and bring objectivity and perspective. I thought I had understood the picture at a macro level but obviously not.

And, I guess it does bring sort of levelling sensibility to the science. Yet, it does seem that there might be something of merit in rvx-208.

From your comments it does seem that the impact of rvx-208 may be modest at best OR like all of the complexities of biological life...the impact is very selective e.g. DM, CVD and low HDL. If it turns out that way that is great.

Thanks again and please keep your incredible insights coming.
Cheers
Toinv

Bullboard Posts

Bitcoin company adds convenience of modern banking